Clinical Trials for Neuroprotection in ALS
The DOI matches its Crossref record.
Abstract
Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only marginal effects on disease survival. Here we review some of the recent advances in the search for disease-modifying drugs for ALS based on their putative neuroprotective effetcs. A number of more or less established agents have recently been investigated also in ALS for their potential role in neuroprotection and relying on antiglutamatergic, antioxidant or antiapoptotic strategies. Among them Talampanel, beta-lactam antibiotics, Coenzyme Q10, and minocycline have been investigated. Progress has also been made in exploiting growth factors for the treatment of ALS, partly due to advances in developing effective delivery systems to the central nervous system. A number of new therapies have also been identified, including a novel class of compounds, such as heat-shock protein co-inducers, which upregulate cell stress responses, and agents promoting autophagy and mitochondriogenesis, such as lithium and rapamycin. More recently, alterations of mRNA processing were described as a pathogenic mechanism in genetically defined forms of ALS, as those related to TDP-43 and FUS-TLS gene mutations. This knowledge is expected to improve our understanding of the pathogenetic mechanism in ALS and developing more effective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anti-apoptosis and cell survival: A review
Portt, L., Norman, G., Clapp, C., Greenwood, M., & Greenwood, M. T. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.10.010 · Cited by 636
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., & Shaw, P. J. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.152 · Cited by 615
Osaki, T., Uzel, S. G. M., & Kamm, R. D. (2018) · Science Advances · doi:10.1126/sciadv.aat5847 · Cited by 421
Neuronal autophagy and neurodegenerative diseases
Son, J. H., Shim, J. H., Kim, K.-H., Ha, J.-Y., & Han, J. Y. (2012) · Experimental & Molecular Medicine · doi:10.3858/emm.2012.44.2.031 · Cited by 348
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications
Banerjee, R., Beal, M. F., & Thomas, B. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.001 · Cited by 199
Metadata
- Authors
- Siciliano, G., Carlesi, C., Pasquali, L., Piazza, S., Pietracupa, S., Fornai, F., Ruggieri, S., & Murri, L.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-07-01
- Volume
- 9
- Issue
- 3
- Pages
- 305-313
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W1996778243
- Cited by
- 48
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Trials for Neuroprotection in ALS. https://app.cochat.ai/papers/10.2174/187152710791292648
- The paper
- Siciliano, G., Carlesi, C., Pasquali, L., Piazza, S., Pietracupa, S., Fornai, F., Ruggieri, S., & Murri, L. (2010). Clinical Trials for Neuroprotection in ALS. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/187152710791292648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.